A critical appraisal of an article on therapy: Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions: an assessor-blinded, randomized controlled clinical trial
Ma. Vinna N. Crisostomo, MD, Mary Jo Kristine S. Bunagan, MD, FPDS
A 23-year-old male diagnosed with Hansen’s disease, BB-BL, was started on multi-drug therapy (MDT). On his 6th month of therapy, he was started on prednisone 40mg/day for management of type 2 lepra reaction.